NicOx reports first quarter 2008 financial results

                   
tmcnet.com     May 14, 2008            

SOPHIA ANTIPOLIS, FRANCE, May 14 / MARKET WIRE/ -- Sophia Antipolis, France. www.nicox.com NicOx S.A. (Eurolist: COX) today reported financial results for the first three months of 2008. On March 31, 2008, the Company had cash, cash equivalents and financial instruments of EUR 153.7 million,... [read full story]                

Full Coverage

NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent...

newsblaze.com     May 13, 2008          

May 13, 2008. Sophia Antipolis, France. www.nicox.com ... Sophia Antipolis, France. www.nicox.com NicOx S.A. (Eurolist: COX) today announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients,...                

comments

NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent...

tmcnet.com     May 13, 2008          

NicOx announces initiation of first phase 1 study of investigational nitric oxide-donating agent in hypertensive patients by Merck & Co., Inc. ... Via Acquire Media NewsEdge) May 13, 2008. Sophia Antipolis, France. www.nicox.com NicOx S.A. (Eurolist: COX) today announced...                

comments

NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent...

redorbit.com     May 13, 2008          

Posted on: Tuesday, 13 May 2008, 03:00 CDT May 13, 2008. Sophia Antipolis, France. www.nicox.com NicOx S.A. (Eurolist: COX) today announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative...                

comments

                   

NicOx reports first quarter 2008 financial results

newsblaze.com     May 14, 2008          

Sophia Antipolis, France. www.nicox.com NicOx S.A. (Eurolist: COX) today reported financial results for the first three months of 2008. On March 31, 2008, the Company had cash, cash equivalents and financial instruments of EUR 153.7 million, compared to EUR 201.2 million on March 31, 2007. Review...                

comments

NicOx Announces Initiation Of First Phase 1 Study Of Investigational Nitric Oxide-Donating Agent...

medicalnewstoday.com     May 14, 2008          

NicOx S.A. (Eurolist: COX) announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies' collaborative agreement to develop new nitric oxide-donating antihypertensive agents using NicOx'...                

comments